

Declaration of Interests Register							
Technology Appraisal Committee A				Publication Date: 13/11/2019			
Topic: TA611 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [ID1485]							
Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Prof. Jonathan Ledermann	Expert adviser	Direct financial	Received advisory board and speaker fees AstraZeneca, Clovis Oncology, Tesaro, Roche and Pfizer, and a research grant for studies with olaparib from AstraZeneca. Global lead for ARIEL3 trial.		July 2019	Ongoing	Declare and participate. Not involved in decision making.
Dr Paul Robinson	Committee member	Director financial	His employer, MSD, is co-developing and marketing olaparib with AstraZeneca, which is a comparator treatment.		July 2019	Ongoing	Excluded from meeting.

Link to Committee A interests register : <https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-A-interests-register.pdf>

#### **GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER**

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.